Pegylated lipid, liposome modified by the lipid, pharmaceutical composition containing the liposome, formulation and application thereof

A PEGylated lipid, wherein, the structure is represented by the general formula (2):

• wherein, L7 and L8 are each independently a linking bond, —OC(═O)— or —C(═O)O—;
• wherein, L3 is a linking bond, -L4-, -L4-Z—, —Z-L4-, —Z-L4-Z—, -L4-Z-L5-, —Z-L4-Z-L5-, -L4-Z-L5-Z—, —Z-L4-Z-L5-Z— or -L4-Z-L4-Z-L5-Z—;
• said L4 and L5 are carbon chain linking groups, each independently represented as —(CRaRb)t—(CRaRb)o—(CRaRb)p—, wherein, t, o and p are each independently an integer from 0 to 12, and t, o and p are not 0 simultaneously;
• Ra and Rb are, at each occurrence, each independently a hydrogen atom or a C1-12 alkyl group;
• said Z is, at each occurrence, each independently selected from the group consisting of —C(═O)—, —OC(═O)—, —C(═O)O—, —OC(═O)O—, —O—, —S—, —C(═O)S—, —SC(═O)—, —NRcC(═O)—, —C(═O)NRc—, —NRcC(═O)NRc—, —OC(═O)NRc—, —NRcC(═O)O—, —SC(═O)NRc—, —NRcC(═O)S—, and
• wherein, Rc is, at each occurrence, independently a hydrogen atom or a C1-12 alkyl group;
• wherein, B3 and B4 are each independently a linking bond or a C1-30 alkylene group;
• wherein, R1 and R2 are each independently a C1-30 aliphatic hydrocarbon group;
• wherein, R is a hydrogen atom, —Rd, —ORd, —NRdRd, —SRd, —C(═O)Rd, —C(═O)ORd, —OC(═O)Rd, —OC(═O)ORd, or
• wherein, Rd is, at each occurrence, independently a C1-12 alkyl group, G1 is a (k+1)-valent terminal branching group, j is 0 or 1, and F contains the functional group R01;
• when j is 0, G1 is absent, and k is 1;
• when j is 1, G1 protrudes F with the number of k, and k is an integer from 2 to 8;
• when L3 is —C(═O)CH2—, R is not a hydrogen atom, an alkyl group, an alkoxy group, or a hydroxyl group;
• wherein, A is —(CRaRb)sO— or —O(CRaRb)s—, wherein, s is 2, 3, or 4;
• wherein, n1 is an integer from 20 to 250;
• said alkyl group, alkylene group, alkoxy group, and aliphatic hydrocarbon group are each independently substituted or unsubstituted.